Search Within

Yelena Yuriy Janjigian

Formats
  1. Meeting Abstract (219)
  2. Journal Article (157)
  3. Review (11)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (403)
  2. Gastrointestinal Oncology Service (403)
  3. Solid Tumor Oncology Division (403)
  4. Center for Pancreatic Cancer Research (161)
  5. Surgery (149)
  6. Department of Pathology and Laboratory Medicine (137)

More Groups

People
  1. David Ilson (112)
  2. Geoffrey Ku (110)
  3. Laura Tang (84)
  4. David Kelsen (74)
  5. Daniela Molena (65)
  6. Steven Maron (65)

More People

Years
  1. 2025 (23)
  2. 2024 (33)
  3. 2023 (42)
  4. 2022 (37)
  5. 2021 (54)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (146)
  2. Annals of Oncology (46)
  3. Annals of Surgical Oncology (14)
  4. Annals of Surgery (13)
  5. Clinical Cancer Research (13)
  6. Oncology Research and Treatment (11)

More Publications

Publishers
  1. American Society of Clinical Oncology (152)
  2. Oxford University Press (53)
  3. American Association for Cancer Research (28)
  4. Springer (22)
  5. Elsevier Inc. (19)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (403)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma
    Meeting Abstract

    Johnson, M. L.; Sima, C.; Paik, P. K.; Janjigian, Y. Y.; Pao, W.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma
    Meeting Abstract

    Ilson, D.; Shah, M. A.; Kelsen, D. P.; Janjigian, Y. Y.; Tang, L. H.; Campbell, J.; Fuqua, L.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma
    Meeting Abstract

    D'Angelo, S. P.; Janjigian, Y. Y.; Kris, M. G.; Pao, W.; Riely, G. J.; Marks, J.; Sima, C.; Dycoco, J.; Park, B. J.; Azzoli, C. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • HER2 status in gastric cancer: Correlation between IHC and FISH
    Meeting Abstract

    Tafe, L. J.; Zaidinski, M.; Hedvat, C.; Tang, L.; Janjigian, Y.; Shah, M.; Barbashina, V.
    Laboratory Investigation (2010)

    Fulltext@MSK | Save
  • HER2 status in gastric cancer: Correlation between IHC and FISH
    Meeting Abstract

    Tafe, L. J.; Zaidinski, M.; Hedvat, C.; Tang, L.; Janjigian, Y.; Shah, M.; Barbashina, V.
    Modern Pathology (2010)

    Fulltext@MSK | Save
  • A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors
    Journal Article

    Janjigian, Y. Y.; Lee, W.; Kris, M. G.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Senturk, E.; Calcutt, M. W.; Rizvi, N. A.
    Cancer Chemotherapy and Pharmacology (2010)

    Fulltext@MSK | Save
  • Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/ IV nonsmall cell lung cancer
    Journal Article

    Janjigian, Y. Y.; Mcdonnell, K.; Kris, M. G.; Shen, R.; Sima, C. S.; Bach, P. B.; Rizvi, N. A.; Riely, G. J.
    Cancer (2010)

    Fulltext@MSK | Save
  • Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
    Journal Article

    De Braganca, K. C.; Janjigian, Y. Y.; Azzoli, C. G.; Kris, M.; Pietanza, M. C.; Nolan, C.; Omuro, A. M.; Holodny, A.; Lassman, A. B.
    Journal of Neuro-Oncology (2010)

    Fulltext@MSK | Save
  • Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
    Meeting Abstract

    Janjigian, Y. Y.; Park, B. J.; Kris, M. G.; Miller, V. A.; Riely, G. J.; Zheng, J.; Dycoco, J. P.; Shen, R.; Azzoli, C. G.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase 1 trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Meeting Abstract

    Riely, G. J.; Janjigian, Y. Y.; Pereira, L. K.; Azzoli, C. G.; Pietanza, M. C.; Krug, L. M.; Rizvi, N. A.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; more...
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save